Enterprise contract lifecycle management software using AI to extract obligations and risks from contracts
Icertis is the largest pure-play enterprise CLM (contract lifecycle management) vendor with ~$350M ARR, +25% YoY growth, and global enterprise customers including Microsoft, Johnson & Johnson, and Daimler. Last private valuation $5B. As of early 2025 the company has reportedly engaged Goldman Sachs to explore a sale or IPO. Competes with Ironclad and DocuSign CLM in the AI-powered CLM category.
SaaS📍 Bellevue, WAFounded 2009
Current Valuation
$5.0B
as of 2025-Q1
UNICORN
QL Price
$3.9B
-22% vs last round
QuantLogix's current estimate for Icertis, published 2026-10-07 — below the last disclosed round of $5.0B (2025-Q1).
Confidence
medium
Basis
blended
What backs this price
Last disclosed round
$5.0B
2025-Q1
weight 0.35
Secondary market print
$3.8B
2026-06-27
weight 0.54
Public-company comparables
$1.4B
2025-FY
weight 0.14
How this price has held up
No round has priced for Icertis since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-10-07 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Icertis, 2026-10-07 (5961459a1f473142).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookrumored
Is Icertis going public in 2027?
An IPO is rumored for 2027, with nothing filed. Icertis remains private and the date is not the company's.
What is Icertis' valuation in 2026?
Icertis is valued at $5.0B as of 2025-Q1, set by its Series F (potential sale process) ($50M, Mar 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Icertis filed an S-1?
No public S-1 is on file for Icertis as of 10/07/2026; the IPO is rumored.
Who are Icertis' investors?
Icertis' investors include B Capital Group, Greycroft, Premji Invest, SoftBank, Meritech Capital.
How much has Icertis raised?
Icertis has raised $525M in total, most recently a Series F (potential sale process) of $50M in Mar 2025.
Is Icertis publicly traded — can you buy Icertis stock?
No. Icertis is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Icertis on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Samir Bodas
Founded
2009
HQ
Bellevue, WA
Employees
~2500
Total Raised
$525M
Est. Revenue
$350M (2025-FY)
Growth
+25% YoY
Last Round
Series F (potential sale process) — $50M (Mar 2025) · Lead: Goldman Sachs (sale advisor)
IPO Status
rumored
Fundraising Status
Series F (potential sale process) · $50M · 1y 7mo ago
rumoredTotal raised $525M
Secondary Market
Implied price / share
$62.54
Last round price / share
$82.64
vs last round
-24.3%
Open interest
2
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series F (potential sale process)
$50M
Mar 2025
Goldman Sachs (sale advisor)
—
Talent Signal
Hiring trend
▶ Hiring steady
-8% vs 2026-08
Open roles
11
via careers page
Product-build share
73%
engineering, research, product, design
Trajectory
steady
heavy product build — 73% of open roles are product-building functions (engineering/research/product) — 5 of 11 open roles are research.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Medical DevicesPharmaceutical & Life SciencesAnalyst & Research Reports[Medical Devices](https://www.icertis.com/solutions/industry-solutions/medical-d[White Papers & eBooks](https://www.icertis.com/research/ebooks/ "White Papers &[The Fine Print](https://www.icertis.com/research/blog/ "The Fine Print")
Counted from Icertis's live job board as of 2026-09-15; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Samir BodasMonish Darda
Investors
B Capital Group · Greycroft · Premji Invest · SoftBank · Meritech Capital
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q1. Refreshed quarterly.